Cardiol Therapeutics Inc. (CRDL) stock
CRDLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.86−0.02 (-2.28%)
Close on Nov 20, 2026Market cap $86.48MP/E –Yield –
Cardiol Therapeutics cash
Cash and short-term investments held at the end of each period.
Cardiol Therapeutics's cash was C$21.42M at Dec 31, 2025. For fiscal 2025 it was C$21.42M, down 30.0% from the year before. The highest annual figure on record is C$83.90M in fiscal 2021.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | C$21.42M | -30.0% |
| FY2024 | Dec 31, 2024 | C$30.58M | -12.5% |
| FY2023 | Dec 31, 2023 | C$34.93M | -41.3% |
| FY2022 | Dec 31, 2022 | C$59.47M | -29.1% |
| FY2021 | Dec 31, 2021 | C$83.90M | +498.2% |
| FY2020 | Dec 31, 2020 | C$14.03M | +101.6% |
| FY2019 | Dec 31, 2019 | C$6.96M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2025 | Dec 31, 2025 | C$21.42M | -74.5% |
| Q4 FY2024 | Dec 31, 2024 | C$30.58M | +118.0% |
| Q4 FY2023 | Dec 31, 2023 | C$34.93M | +402.2% |
| Q4 FY2022 | Dec 31, 2022 | C$59.47M | – |
| Q4 FY2021 | Dec 31, 2021 | C$83.90M | – |
| Q4 FY2020 | Dec 31, 2020 | C$14.03M | – |
| Q4 FY2019 | Dec 31, 2019 | C$6.96M | – |
See a number that looks wrong?